Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics.
Kiwan Kim, Seong-Won Song, Yeongha Jeon et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-centre, open-label phase I trial assessed intravenous autologous IL13Rα2-targeted CAR T cells in adults with recurrent, IL13Rα2-expressing grade 3–4 gliomas after standard treatment. Ten patients received one infusion across three dose cohorts. No dose-limiting toxicities occurred, and the maximum tolerated dose was not reached; adverse events were grade 3 or lower without irreversible sequelae. Among six patients assessed for response at 3 months, best response was stable disease in three. Median progression-free survival was 2.6 months [95% CI, 0.95-5.75] and median overall survival was 10.9 months [95% CI, 8.2-26.6].
Key findings
- No dose-limiting toxicities were observed, so the maximum tolerated dose was not reached; all adverse events were grade ≤3 without irreversible sequelae.
- Pyrexia and elevated transaminase were the most common treatment-related adverse events, each occurring in 70%.
- CAR T-cell levels in blood peaked at a median of 7 days (range, 3-14); transgene was detected in cerebrospinal fluid in 5 of 6 patients at the two higher doses.
- Among six patients assessed for response at 3 months, three had stable disease; median PFS was 2.6 months [95% CI, 0.95-5.75] and median OS was 10.9 months [95% CI, 8.2-26.6].
Why it matters
The trial provides early human safety and pharmacokinetic data for an intravenous, antigen-targeted cellular therapy in recurrent malignant glioma, a setting with limited treatment options. The absence of dose-limiting toxicity is encouraging for further investigation, while the small cohort and limited response assessment mean the survival and disease-control findings should be viewed as preliminary rather than evidence of efficacy.
What to keep in mind
This was a single-centre phase I trial involving 10 patients, with no comparator. Response assessment at 3 months was available for only six patients, limiting conclusions about efficacy.